Acurx Pharmaceuticals, Inc. Share Price & Technical Analysis
ACXP · $1.94 (-1.52%)
Healthcare / Biotechnology
$1.94
-1.52%
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections in the United States. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potentia…
Price chart
Seasonality
May has 2 positive and 3 negative years (last 5 years shown)
-13% return in May, 3% avg return in past 3 year May month.
52% return in 2026, -51% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -4% | -37% | 147% | -41% | -13% | – | – | – | – | – | – | – | 52% |
| 25 | -14% | -4% | -44% | 9% | -9% | 32% | -36% | -28% | -7% | 16% | -24% | -36% | -144% |
| 24 | -16% | -14% | -18% | -9% | 14% | -11% | -3% | 0% | -14% | 1% | -35% | -34% | -140% |
| 23 | -9% | -5% | 5% | -14% | 4% | -12% | -26% | -6% | -23% | 241% | -33% | 9% | 130% |
| 22 | -7% | -14% | -10% | 10% | -24% | 50% | -6% | -4% | -14% | 3% | 0% | 25% | 7% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Downtrend · Neutral
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections in the United States. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus (MRSA), vancomycin resistant enterococcus (VRE), and drug-resistant streptococcus pneumoniae (DRSP), as well as B. anthracis. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$5.58M
P/E ratio
—
52W high
$21.00
52W low
$1.33
Volume
78,727
Beta
-2.09
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Acurx Pharmaceuticals, Inc. share price today?
- Acurx Pharmaceuticals, Inc. (ACXP) last traded around $1.94 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does ACXP have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for ACXP. Download the app for real-time alerts.
- How can I analyze Acurx Pharmaceuticals, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.